Research programme: anti-inflammatory therapeutics - Noxopharm/Hudson Institute of Medical Research
Latest Information Update: 28 Apr 2025
At a glance
- Originator The Hudson Institute of Medical Research
- Developer Noxopharm; The Hudson Institute of Medical Research
- Class Anti-inflammatories
- Mechanism of Action STING1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 25 Mar 2025 Noxopharm expands collaboration with Hudson Institute of Medical Research to advance Sofra™ platform
- 27 Mar 2023 Early research in Autoimmune disorders in Australia (Noxopharma pipeline, March 2023)
- 25 Nov 2022 Noxopharm collaborates with Hudson Institute of Medical Research to develop anti-inflammatory compounds